Starting a HCT program A perspective from India Alok Srivastava Department of Haematology Christian Medical College
1 Personnel 2 Institutional Support 3 Physical Environment 4 Medical Infrastructur e Successful HSCT Program 6 Phased Development 7 Business Model 5 Protocols & SOPs Establishing a successful HSCT program
Establishing a successful HSCT program 1.Developing appropriate personnel 1.Physicians Comprehensive training (2-3 years) in hematology and transplantation (Most critical) 2.Resident physicians 3.Nurses Very critical component, need a team, 1 to 1 nursing, if possible 4.Consultative support Histopathology, Radiologists, Clinical consults: Gastroenterology, Nephrology, Neurology, Cardiology, others 5.Apheresis / cryopreservation staff 6.Transplant coordinators / counselors 7.Housekeeping staff / Engineers
Establishing a successful HSCT program 2.Physical Environment 1.Transplant rooms HEPA filtered 2.Water clean 3.Food supply?sterile 4.Support departments Central sterile supply 5.Protocols for entry / exit 6.Protocols for housekeeping 7.Microbiological monitoring of air and water
Streets around CMC, Vellore CHRISTIAN MEDICAL COLLEGE, VELLORE, INDIA (ESTD: 1900)
Establishing a successful HSCT program 3.Institutional support 1.Critical for developing the - team of personnel - physical environment for HSCT - medical infrastructure 2.Provide necessary space and financial support for establishing infrastructure for what may appear esoteric at first
Establishing a successful HSCT program 4.Medical infrastructure 1.HLA typing Institutional / outsourced 2.Insertion of Hickman / Broviac catheters 3.Blood bank with components platelets / plasma 4.Apheresis instruments for PBSC / platelets 5.Blood irradiation facilities 6.Round the clock laboratory services: Hematology (Flowcytometry / Molecular genetics graft assessment / chimerism) Biochemistry Microbiology bacterial / fungal / viral infections (quantitation, if possible) 7.Pharmacy services: Drugs / TPN / other requirements
Establishing a successful HSCT program 5.Establishing protocols and SOPs Important to have clearly defined policies and protocols for everything 1.Pre-transplant evaluation (recipient & donor) 2.Conditioning regime 3.Harvest of stem cells BM / PBSC 4.Cultures and antibiotics prophylaxis, if any 5.GVHD prophylaxis and (?treatment) 6.Post-transplant follow-up and care Taper of GVHD prophylaxis Monitoring of engraftment / chimerism Immunization protocol 7.Long term follow-up protocols 8.Systematic data recording for analysis and quality management
Establishing a successful HSCT program 6.Phased development 1.Build team through practice of intensive hematology managing chemotherapy and cytopenias with transfusions / antibiotics / other supportive measures 2.Careful selection of initial patients 3.Start with autologous, if possible, for multiple myeloma and then lymphomas when cryopreservation becomes possible. 4.Move to matched related allogeneic transplants in good risk patients before doing high risk / alternative donor transplants 5.Collegial atmosphere for discussion / questions in the team 6.Keep up with relevant literature and technology, as much as possible Introduce research into clinical practice 7.Develop a team that communicates well patients and
Establishing a successful HSCT program 7.The business model (if relevant) 1.Even if fully supported by government funds, need to evolve a program that is financially sustainable within that health care system 2.If in the private sector (insurance / self pay), need to develop a cost structure that allows even those with limited resources to access the program
1986 (1 bed) 1990 (3 beds) Phased development of the Stem Cell Transplant Unit at CMC, Vellore, India 2008 10+8 beds
BONE MARROW TRANSPLANTATION CMC (Oct 1986 - Dec 2010) 160 140 120 100 80 60 40 20 0 1986 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 No. of transplants Years Allogeneic-1004 Autologous-306 -Matched related : Avg cost -US $ 20,000 -Matched unrelated (since 2008) : Avg cost US $ 50-100,000 -Haplo identical (since 2006) : Avg cost US $ 20-50,000
INDICATIONS FOR BMT CMC, Vellore (Oct 1986 - Dec 2010) Allogenic transplant (n=1004) Myelodysplastic Syndrome 5% Acute Lyphoblastic Leukemia 8% Myelofibrosis 1% FA 1% PNH 1% APML 1% Other Malignancies <1% PRCA <1% Thalassemia 34% Chronic Myeloid Leukemia 12% Aplastic Anaemia 16% Rare genetic disorder 1% (Diamond Blackfan-3 Severe Combined Immuno Deficiency-3 Wiscott Aldrich Syndrome-4 Dyskeratosis congenita-1 Osteopetrosis-1 Adrenoleukodystrophy-1 Kostmann Syndrome-1 Congenital Sideroblastic anaemia-1) Acute Myeloid Leukemia 20%
INDICATIONS FOR BMT CMC, Vellore (Oct 1986 - Dec 2010) Autologous Transplant (n=306) Acute Promyelocytic Leukemia 8% Hodgkin Lymphoma 11% Acute Lymphoblastic Leukemia 1% Amyloidosis Plasma cell Leukemia 1% 1% Granulocytic Sarcoma <1% Multiple Myeloma 43% Acute Myeloid Leukemia 17% Non-Hodgkin's Lymphoma 18%
(LUDHIANA) Dr. Joseph John (NEW DELHI) Dr. Velu Nair Dr. Dinesh Bhurani Dr. Satyaranjan Das Dr. Sanjeevan Sharma (SRINAGAR) Dr. Gh Jeelani Samoon Dr. Javid Rassol Bhat (AHMEDABAD) Dr. Urmish Chudgar Dr. Ashwin Patel Dr. Uday R Deotare (BHOPAL) Dr. Sunil Dabadghao (AURANGABAD) Dr. Jayant Indurkar (MUMBAI) Dr. Farah Jijina Dr. Abhay Bhave Dr. Sameer Shah (PUNE) Dr. S.J. Apte Dr. Ajay Sharma Dr. Vijay Ramanan Dr. Sameer Melinkeri Dr. Kannan. S (COCHIN) Dr. Manoj Unni (TRIVANDRUM) (INDORE) Dr. Anil Singhvi (KOLKATA) Dr. Suparno Chakraborty Dr. Siddhartha Sankar Ray Dr. Anupam Chakrapani (BHUBANESHWAR) Dr. P.K. Das (HYDERABAD) Dr. A.M.V.R. Narendra Dr. Shailesh R Singhi Dr. Ravindra Votery (BENGALURU) Dr. Cecil Ross Dr. Sharat Damodar (CHENNAI) Dr. Krishnarathnam. K (COIMBATORE) Dr. Suthanthira Kannan Dr. Shruti Prem
Stem Cell Transplant Centers in India - 2011 Ludhina Chandigarh Delhi Lucknow Ahmedabad Kolkata Mumbai Pune Hyderabad TRANSPLANT CENTERS IN INDIA Bangalore Manipal Chennai Vellore 2001-2005 1996-2000 1991-1995 4 9 15 Trivandrum PRE 1990 3
INDIAN STEM CELL TRANSPLANT REGISTRY Number of Transplants India (N=4015) 700 600 Allo (N=2445) Auto (N=1569) 500 242 400 300 204 187 141 144 147 200 100 0 108 346 66 1 3 2 1 0 1 4 2 5 17 35 39 47 38 59 85 76 91 93 123 101 143 184 229 251 275 53 56 55 34 52 194 26 6 12 13 17 3 2 1 No. of transplants 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 Years
700 600 500 400 300 200 100 0 INDIAN STEM CELL TRANSPLANT REGISTRY Number of Transplants India (N=4015) 588 479 438 328 341370 1 3 2 1 0 1 4 5 7 18 41 51 60 55 85 119128144 149 190 156 251 No. of transplants 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 Years
INDIAN STEM CELL TRANSPLANT REGISTRY No. of transplants 1200 1100 1000 900 800 700 600 500 400 300 200 100 0 306 1004 198 109 139 269 241 228 ALLO (2445) AUTO (1569) 244 59 154 8 21 82 121 91 86 86 16 68 51 47 10 33 25 22 21 3 39 67 18 16 12 4 12 6 10 6 14 8 61 26 34 1 07 30
Starting a HCT program A perspective from India Possible to establish a state of the art facility for SCT if there are the -Right people -Strong commitment -Supportive institutional environment -Disseminate expertise to the rest of the country Our team Physicians: 6 Scientists: 4 Registrars: 15 Research Fellows: 20 Nurses: 22 Transplant / Research coordinators